miR-340 suppresses glioblastoma multiforme

Daquan Huang; Shuwei Qiu; Ruiguang Ge; Lei He; Mei Li; Yi Li; Ying Peng

doi:10.18632/oncotarget.3288

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-340 suppresses glioblastoma multiforme

Daquan Huang _, Shuwei Qiu, Ruiguang Ge, Lei He, Mei Li, Yi Li and Ying Peng

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:9257-9270. https://doi.org/10.18632/oncotarget.3288

Metrics: PDF 2678 views | HTML 2789 views | ?

Abstract

Daquan Huang1,2*, Shuwei Qiu1*, Ruiguang Ge3, Lei He1, Mei Li1, Yi Li1, Ying Peng1,2

1Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

2Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

3Key Laboratory of Gene Engineering of the Ministry of Education and State Key Laboratory of Biocontrol, College of Life Sciences, Sun Yat-Sen University, Guangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Ying Peng, e-mail: [email protected]

Keywords: glioblastoma multiforme, miR-340, ROCK1, biomarker

Received: January 07, 2015 Accepted: February 07, 2015 Published: March 16, 2015

ABSTRACT

Deregulation of microRNAs (miRs) contributes to tumorigenesis. Down-regulation of miR-340 is observed in multiple types of cancers. However, the biological function of miR-340 in glioblastoma multiforme (GBM) remains largely unknown. In the present study, we demonstrated that expression of miR-340 was downregulated in both glioma cell lines and tissues. Survival of GBM patients with high levels of miR-340 was significantly extended in comparison to patients expressing low miR-340 levels. Biological functional experiments showed that the restoration of miR-340 dramatically inhibited glioma cell proliferation, induced cell-cycle arrest and apoptosis, suppressed cell motility and promoted autophagy and terminal differentiation. Mechanistic studies disclosed that, miR-340 over-expression suppressed several oncogenes including p-AKT, EZH2, EGFR, BMI1 and XIAP. Furthermore, ROCK1 was validated as a direct functional target miR-340 and silencing of ROCK1 phenocopied the anti-tumor effect of mR-340. Our findings indicate an important role of miR-340 as a glioma killer, and suggest a potential prognosis biomarker and therapeutic target for GBM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3288

Publication Alerts

Research Papers:

miR-340 suppresses glioblastoma multiforme

Abstract